Full Length Research Paper

Potential of colloidal or silver nanoparticles to reduce the growth of B16F10 melanoma tumors

Sierra-Rivera C. A., Franco-Molina M. A.*, Mendoza-Gamboa E., Zapata-Benavides P., Tamez-Guerra R. S. and Rodríguez-Padilla C.

Laboratorio de Inmunología y Virología, Departamento de Microbiología e Inmunología, Facultad de Ciencias Biológicas de la Universidad Autónoma de Nuevo León, San Nicolás de los Garza, N. L. México.

Accepted 26 March, 2013

Previously, we reported the cytotoxic effect of colloidal silver (AgC) on MCF-7 breast cancer cell line. However, there is scarce information on its antitumor potential. The aim of this study was to evaluate the anti-tumoral activity of colloidal silver (AgC) or silver nanoparticles (AgNPs) in a B16F10 melanoma mice model. In vitro, B16F10 cells were treated with different concentrations of AgC or AgNPs and cell viability was evaluated by MTT method, both treatments had cytotoxic effects against B16F10 cell line. In vivo, B16F10 melanoma cells (5 × 10⁵) were implanted in six weeks old C57BL/6 mice. About 8 days after cells injection, the subcutaneous treatments were started with AgC or AgNPs, tumor volume and tumor weight were evaluated and the difference of treated groups and control demonstrated that melanoma tumor growth was significantly decreased. Our results suggest that AgC or AgNPs could be useful as an antiproliferative drug, inducing an impairment of tumoral growth.

Key words: Colloidal silver, silver nanoparticles, melanoma, cancer, tumor.

INTRODUCTION

The recent increase in the incidence of malignant melanoma urges the development of more specific and effective therapies. Historically, silver has been a major therapeutic agent in medicine, especially in infectious disease, including surgical infections (Alexander, 2009). Since 1990, there has been a resurgence on the use of AgC as an alternative medicine because of increased resistance of bacteria to antibiotics, and the continuing search for novel and affordable antimicrobial agents. Previously, we reported that AgC has antitumor activity through induction of apoptosis in MCF-7 breast cancer cell line (Franco-Molina et al., 2010) and other studies with AgNPs, by Sriram et al. (2010) demonstrated the efficacy of biolo-synthesized AgNPs as an antitumor agent against Dalton’s lymphoma ascites cell lines in vitro and in vivo and the capacity to affect cellular viability of human colon cancer cells (HT 29) (Sanpui et al., 2011). Despite the fact that nanoparticles and colloidal particles possess great potential for future clinical application therapeutics, and this application generated interest in exploring other metals for potential anti-cancer properties (Bhattacharyya et al., 2011), there is scarce information on AgC or AgNPs antitumor potential. This study is relevant due to their use within health remedies. The aim of the present study was to determine the effects of AgC or AgNPs on murine melanoma tumorigenesis under in vitro and in vivo conditions.

*Corresponding author. E-mail: moyfranco@gmail.com. Tel: 01152-81-83-29-41-15. Fax: 01152- 81-83-52-42-12.

Abbreviations: AgC, Colloidal silver; AgNPs, silver nanoparticles; MTT, thiazoly blue tetrazolium bromide.
MATERIALS AND METHODS

Animals

In vivo experiments were conducted in male C57BL/6 mice of six weeks old (18 to 25 g), housed at 22 ± 2°C under a 12/12 h light/dark cycle with free access to food and water until use. All animal handling and experimental procedures were conducted with prior approval of the ethics committee on animal use of the Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León.

AgC or AgNPs

The greenetin-stabilized AgC (120 nm) was purchased from MICRODYN (Mexico, D.F.) as a 0.25% stock solution. It was filtered and diluted to a concentration of 17.5 µg/mL with DMEM/F-12 supplemented with 10% FBS. The AgNPs (10 nm) was purchased from (Nanostructured & Amorphous Materials Inc. Houston, Tx. USA); 5 mg/mL stock solution was prepared in DMEM-F-12 supplemented with 10% FBS, previously sonicated during 15 min for its homogenization and sterilized by filtration (0.2 µm filter, Millipore, USA) in vitro for assays. For in vivo studies, 28 mg/kg (AgC) or 1000 mg/kg (AgNPs) per mice were daily administered subcutaneously around the tumor.

Cell viability

Cells (5 x 10² cells/well) were plated on 96 flat-bottom well plates, and incubated 24 h at 37°C in 5% CO₂ atmosphere. After incubation, culture medium was removed, and AgC diluted in the same medium was added at concentrations ranging from 0 to 17.5 µg/mL and AgNPs at concentrations ranging from 0 to 5 mg/mL. The plates were then incubated for 24 h at 37°C, and 5% CO₂ atmosphere. Thereafter, the supernatant was removed and cells were washed twice with DMEM/F-12 medium. Cell viability was determined by the MTT method. Quantification was obtained by the absorbance reading at a wavelength of 570 nm and cellular viability was expressed as percentage. Results were given as the mean ± SD of three independent experiments.

Melanoma cells implant

All animal procedures were made in Laboratorio de Inmunología de la Facultad de Ciencias Biológicas de la UANL, in accordance with Facultad de Ciencias Biológicas of the UANL Ethics Committee. Briefly, 5 x 10⁵ B16F10 melanoma cells were injected subcutaneously into C57BL/6 mice. When tumors were palpable (around 8 days after implanted) mice were treated around tumor with subcutaneous daily dose of 28 mg/Kg of AgC or 1000 mg/Kg of AgNPs. The mice were monitored until 21 days post-cell inoculation and were sacrificed by cervical dislocation (Figure 1). The tumors were surgically collected, and body weight, volume, tumor weight and metastasis were determined (metastasis was deter-mined during the necropsy by findings of tumor cells in muscle, peritoneal cavity, bowel and liver). Tumor volume was recorded using a measuring gauge (PRETUL, USA) using the formula: volume = length x (width)².

Statistical analysis

Data represent the mean ±SD of triplicates from three independent experiments. Statistical differences were obtained using the analysis of variance, and the Dunnett's tests (SPSS v. 17.0 program). The results were considered statistically significant if the “p value was <0.05.

RESULTS

Cytotoxic activity of AgC or AgNPs on B16F10 melanoma cell line

AgC induced dose-dependent cytotoxic effect (7 to 17.5 µg/mL) on B16F10 cells (Figure 2). AgNPs induced dose-dependent cytotoxic effect (1.5 to 5 mg/mL) on B16F10 melanoma cells in 24 h of incubation (Figure 3).

Treatment of B16F10 melanoma tumor

The B16F10 melanoma model was used to demonstrate the therapeutic value of AgC or AgNPs. After the tumor appearance by the eight day, the group mice were daily treated with 28 mg/kg of AgC or AgNPs 1000 mg/kg, respectively, by subcutaneous route around tumor. The mice were sacrificed at 21 days of treatment (Figure 1). There was no difference regarding the body weight between treatments (control (25.00 g ± 2.78), AgNPs (21.30 g ± 1.14) and AgC (25.81 g ± 0.39) (Table 1 and Figure 4). However, these treatments significantly (p<0.05) decreased the tumor weight (AgNPs (0.51 ± 0.22 g) and AgC (0.85 ± 0.64 g)) when compared with the control (4.97 g ± 0.31) (Table 1 and Figure 4); and the tumor
volume was significantly (p<0.05) decreased [(AgNPs (1.21 mm$^3$ ± 0.68) and AgC (1.30 mm$^3$ ± 0.73)) when compared with the control (11.01 mm$^3$ ± 0.86) (Table 1 and Figure 4). Regarding to the necropsy findings; the treatments of AgC or AgNPs prevented the metastasis from muscle, peritoneal cavity, bowel, and liver when compared with control (Table 2). None mice showed tumoral eradication in both groups treated. The mice
Figure 4. Tumor growth decrease in mice treated with AgC or AgNPs. C57BL/6 mice bearing B16F10 tumor were treated daily with AgNP’s or AgC at doses of 28 and 1000 mg/kg, respectively. A) Control, B) AgC and C) AgNPs, these pictures are representative mice groups.

Table 1. Comparison of volume-weight of tumors in mice treated with AgC or AgNPs.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Body weight (g ± SD)</th>
<th>Tumor weight (g ± SD)</th>
<th>Tumor volume (mm³ ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>25.00±2.78</td>
<td>4.97±0.31</td>
<td>11.01±0.86</td>
</tr>
<tr>
<td>AgC</td>
<td>25.81±0.39</td>
<td>0.85±0.64*</td>
<td>1.30±0.73*</td>
</tr>
<tr>
<td>AgNPs</td>
<td>21.30±1.14</td>
<td>0.5±0.22*</td>
<td>1.21±0.68*</td>
</tr>
</tbody>
</table>

C57BL/6 mice bearing B16F10 tumor were daily treated with AgNPs or AgC at doses of 1000 or 28 mg/kg, respectively. In this study, the mice were sacrificed at 21 days. *p<0.05 as compared to the controls.

Table 2. Incidence of metastasis in mice treated with AgC or AgNPs

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Muscle</th>
<th>Peritoneal cavity</th>
<th>Bowel</th>
<th>Liver</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>AgC</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>AgNPs</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

C57BL/6 mice bearing B16F10 tumor, were treated daily with AgNPs or AgC at doses of 1000 or 28 mg/kg, respectively. In this study, the mice were sacrificed by cervical dislocation at 21 days; and the metastasis was determined during the necropsy in muscle, peritoneal cavity, bowel and liver. +: Metastasis, -: without metastasis.

treated with AgC showed a skin induration like fibrosis in the zone treated for five days, this condition was observed until sacrifice; the mice treated with AgNPs were not affected by this symptoms.

DISCUSSION

Skin cancer is the most common form of cancer in the United States. More than 3.5 million skin cancers in over two million people are diagnosed annually. Each year there are more new cases of skin cancer than the combined incidence of cancers of the breast, prostate, lung and colon. An estimated 123,590 new cases of melanoma were diagnosed in the US in 2011: 53,360 noninvasive (in situ) and 70,230 invasive, with nearly 8,790 resulting in death (http://www.skincancer.org). Some cytotoxic agents used for its treatment are costly and known to induce several side effects such as myelosup-
pression, anemia and most importantly the generation of cellular resistance. For this, it is important to find alternative therapies or drugs to overcome these drawbacks (Kim et al., 2007). Since ancient times, the silver has been used to treat numerous diseases, mainly used in antimicrobial agents, in treating wounds, burns and catheter related infections (AshaRani et al., 2009), however; it was until only a few years ago that there was boom in taking different silver particles due to the rate of exposure increasing progressively over the years when engineered nanomaterials were extensively used in a variety of industries including medical applications (AshaRani et al., 2012). The use of smaller particles have a wider tissue distribution, penetrate further within the skin and intestine, are internalised to a greater extent, and have a larger toxic potency (Johnston et al., 2010). So the study of different silver particles is vital to explore their therapeutic potential. Previously, we reported the antitumor activity of colloidal silver on MCF-7 human breast cancer cells (Franco-Molina et al., 2010), and for this reason we decided to continue with a tumor model In vivo. In the present study, our In vitro results demonstrated that AgC or AgNPs significantly decreased in a dose-dependent manner (p<0.05), the growth of B16F10 melanoma cells. The effects of cytotoxicity are similar to those shown by other studies (Hsin et al., 2008) and the mechanism of cell death probably are due to decreased mitochondrial membrane potential, inducing apoptotic death (Franco-Molina et al., 2010). Although, the exact mechanism of action of silver particles is unknown; some reports showed that AgNP uptake occurs mainly through endocytosis where clathrin mediated process and macro-pinocytosis were involved, the nuclear deposition of AgNP is unknown, but the AgNP treatment leads to changes in the cell membrane permeability, facilitating the entry of Ca\(^{+}\) ions which activate enzymes like pro- teases and endonuclease that increase toxicity, resulting in mitochondrial membrane dysfunction and reactive oxygen species production and oxidative stress, damage to DNA can be induced through binding of DNA or via oxidative to DNA, reducing DNA synthesis and producing chromosomal aberrations, errors in chromsome segregation and production of micronuclei, leading to cell death (AshaRani et al., 2009), mainly observed in tumor cells and not in normal cells (Franco-Molina et al., 2010). It is important to notice that major doses were used to induce cytotoxic effect by AgNPs (1.5 to 5 mg/mL) when compared with AgC (7 to 17.5 µg/mL) on cancer cells. This findings were probably due to the fact that AgNPs treated cells have limited exposure to Ag ions because AgNPs solution contained a minimum amount of free Ag ions. However, it has been suggested that AgNPs and Ag can induce cell death in vitro through a ROS production. It has been demonstrated that there are some differences in their mechanism of action, example is that Ag induced metallothionein 1b (MT1b) and AgNPs did not. Ag also is capable of inducing a major production of oxidative stress related glutathione peroxidase and catalase expression compared with AgNPs. This mechanism of action could indicate that AgC appeared more toxic than AgNPs such has been demonstrated by Hsin et al., 2008.

*In vivo* we found that AgC or AgNPs have the potential to impair the growth tumor, since AgNPs is better than AgC treatment in reducing the tumoral volume and weight. These finding could be correlated with another study where the AgNPs had the potential of inhibiting the VEGF in a model employing bovine retinal endothelial cells *in vitro* and angiogenesis in a mice model *in vivo* (Gurunathan et al., 2009). At the beginning of the study, we observed that intraperitoneal injection of AgC (28 mg/kg) induced mice exhibited nervous symptoms after 15 s of administration, like jumping and disnea by 10 min and lethargy during all day long (data not shown), by this reason the use of subcutaneous administration at doses of 28 mg/kg, without side effects was decided, avoiding increases of the doses like that used with AgNPs. There are reports that show adverse effects when doses higher than 100 mg/kg of AgC were used (Faust, 1992). And the adverse effects could be possible because the Ag can enter through the blood-brain barrier and accumulate in large motoneurones in the brain stem and spinal cord, neurons in cerebellar nuclei and glia; and the toxic symptoms such as cerebral ataxia are associated with prolonged exposure to silver (Panyala et al., 2008), which is different from the findings previously mentioned by us.

In this experiment, we used the highest doses reported for AgNPs because in a study by Rahman et al. (2009) on the effects of AgNPs (25 nm) on gene expression in different regions of the mouse brain where the particles were administered to adult male mice route intraperitoneal injection at doses of 100, 500, or 1000 mg/kg for 24 h, array data indicated changes in the expression of genes in the caudate nucleus, frontal cortex and hippocampus of mice treated with the AgNPs. Analysis of these changes led the authors to suggest that AgNPs may produce neurotoxicity by stimulating oxidative stress generation and altered gene expression, leading to apoptosis (Rahman et al., 2009). In the present study, despite the use of AgNPs daily for thirteen days, we did not find adverse effects, like nervous symptoms associated at its administration.

Although, the mechanism of the antitumoral action of AgC or AgNPs is not properly understood, it has been reported that heavy metals react with proteins by getting attached to the thiol group and the proteins get inactivated through a mechanism implicated in avoiding the cellular proliferation of cancer cells (Liau et al., 1997).

With these results, we can confirm the potential of AgC or AgNPs on this melanoma tumor model suggesting them as a potential agent for use in cancer treatment.

REFERENCES

Alexander JW (2009). History of the Medical Use of Silver. Surgical
Infection, 10: 289-292.